Education
About Us
Working with TipRanks
Follow Us
Immunocore Holdings (IMCR)
NASDAQ:IMCR
IMCR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$27.19 - $66.00
Previous CloseN/A
Volume28.13K
Average Volume (3M)324.81K
Market Cap
$1.48B
Enterprise Value$1.22B
Total Cash (Recent Filing)$455.73M
Total Debt (Recent Filing)$432.72M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
May 07, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding50,068,127
10 Day Avg. Volume488,802
30 Day Avg. Volume324,812
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.83
Price to Cash Flow (P/CF)38.00
P/FCF Ratio27.50
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.98
Enterprise Value/Ebitda-20.40
Forecast
1Y Price Target
$69.22Price Target Upside134.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Immunocore Holdings News
PremiumCompany Announcements
Immunocore Holdings Reveals Promising HIV Trial Results
PremiumCompany Announcements
Immunocore Reports 2024 Growth and Strategic Advances---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe STRIVE initial data position Immunocore’s ImmTAV approach as a leading functional cure strategy in Human Immunodeficiency Virus (HIV) infection.
EfficacyThe initial data for IMC-M113V showed promising signs of efficacy, such as lowering HIV viral load, hinting at its potential as a functional cure for HIV.
Mechanism Of ActionIMC-M113V is the first TCR bispecific candidate for HIV, introducing a completely new and novel mechanism of action.
Bears Say
Dose ResponseIMC-M113V treatment did not demonstrate a clear dose response in antiviral activity.
Safety ConcernsMore severe CRS could be dose-limiting.
Viral Control ChallengesInitial MAD data showed modest HIV reservoir reduction and unclear long-term viral control following anti-retroviral therapy interruption.
---
Ownership Overview
― Insiders
33.26% Mutual Funds
51.20% Other Institutional Investors
14.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMCR FAQ
What was Immunocore Holdings’s price range in the past 12 months?
Immunocore Holdings lowest stock price was $27.19 and its highest was $66.00 in the past 12 months.
What is Immunocore Holdings’s market cap?
Immunocore Holdings’s market cap is $1.48B.
When is Immunocore Holdings’s upcoming earnings report date?
Immunocore Holdings’s upcoming earnings report date is May 07, 2025 which is in 38 days.
How were Immunocore Holdings’s earnings last quarter?
Immunocore Holdings released its earnings results on Feb 26, 2025. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.228 by -$0.242.
Is Immunocore Holdings overvalued?
According to Wall Street analysts Immunocore Holdings’s price is currently Undervalued.
Does Immunocore Holdings pay dividends?
Immunocore Holdings does not currently pay dividends.
What is Immunocore Holdings’s EPS estimate?
Immunocore Holdings’s EPS estimate is -0.38.
How many shares outstanding does Immunocore Holdings have?
Immunocore Holdings has 50,068,127 shares outstanding.
What happened to Immunocore Holdings’s price movement after its last earnings report?
Immunocore Holdings reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.228. Following the earnings report the stock price went up 5.341%.
Which hedge fund is a major shareholder of Immunocore Holdings?
Currently, no hedge funds are holding shares in IMCR
---
Immunocore Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$69.22 (134.01% Upside)
$69.22 (134.01% Upside)
Blogger Sentiment
Bullish
IMCR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 238.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $24.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.49%
12-Months-Change
Fundamentals
Return on Equity
-13.92%
Trailing 12-Months
Asset Growth
69.10%
Trailing 12-Months
Company Description
Immunocore Holdings
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
---
IMCR Company Deck
---
IMCR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance in revenue growth and global expansion of KymTrak, as well as promising advancements in clinical trials and a solid financial position. However, challenges in European reimbursement and uncertainties in HIV treatment results were noted. The overall sentiment is predominantly positive due to significant achievements outweighing the challenges.Read More>---
IMCR Stock 12 Month Forecast
Average Price Target
$69.22
▲(134.01% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
Best Analysts Covering IMCR
1 Year
1 Year Success Rate
5/12 ratings generated profit
1 Year Average Return
+5.97%
reiterated a buy rating 3 months ago
Copying Jessica Fye's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +5.97% per trade.
---